Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to
Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.
Following completion of the Month 12 study visit procedures, subjects will be offered the
opportunity to participate in a 2-month observational (i.e., non-interventional) trial
extension.